This site is intended for healthcare professionals
News

PACIFIC phase III trial data at ESMO showed an estimated 35% of non-small cell lung cancer patients treated with Imfinzi had not progressed after four years.- AstraZeneca

Read time: 1 mins
Last updated:16th Mar 2021
Published:19th Sep 2020
Condition: Non Small Cell Lung Cancer
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest